Patient Group: Patient partners who have indicated interest and those enrolled in the study
Regions: British Columbia, Alberta, Ontario
Glomerulonephritis (GN) is a group of relatively rare diseases, yet is one of the most important causes of kidney failure in Canada, striking patients during the prime of their lives. Early effective treatments can halt progression of GN entirely, prevent kidney failure, and reduce the personal and societal burden associated with these diseases. Yet several barriers exist that challenge GN care.
We will address these challenges by creating a network to develop personalized treatments for patients with GN and to identify new markers of high-risk, potentially progressive GN. To do this, we will build upon an established research program to develop a collaborative national patient-centered program. We will make a successful clinical database structure available to the Canadian research community to expand Canadian GN capacity for collaborative bench-to-bedside research. Patients enrolled in our study will be seen every six months for blood tests and updates regarding their health and well-being. This information will be used to develop strategies for personalized treatment. Specifically, we will begin by testing whether genetic and protein markers can predict kidney disease progression and response to innovative treatments. Once the infrastructure is ready and the protocol approved, we will begin recruitment of 350 patients with GN.